CN101622276B
(zh)
|
2006-07-18 |
2015-04-22 |
赛诺菲-安万特 |
用于治疗癌症的抗epha2的拮抗抗体
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
SI2019104T1
(sl)
*
|
2007-07-19 |
2013-12-31 |
Sanofi |
Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
|
GB0819097D0
(en)
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
EP3360879A1
(en)
*
|
2009-02-05 |
2018-08-15 |
ImmunoGen, Inc. |
Benzodiazepine derivatives as cytotoxic agents
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
FR2949469A1
(fr)
*
|
2009-08-25 |
2011-03-04 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application en therapeutique
|
AR078470A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
Anticuerpos que se unen especificamente al receptor epha2
|
CN102933231B
(zh)
|
2010-02-10 |
2015-07-29 |
伊缪诺金公司 |
Cd20抗体及其用途
|
AU2011239522B2
(en)
*
|
2010-04-15 |
2014-10-23 |
Medimmune Limited |
Targeted pyrrolobenzodiazapine conjugates
|
AU2011239525B2
(en)
*
|
2010-04-15 |
2015-04-09 |
Medimmune Limited |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
KR101738203B1
(ko)
*
|
2010-04-15 |
2017-05-19 |
메디뮨 리미티드 |
피롤로벤조디아제핀 및 그의 컨주게이트
|
FR2963007B1
(fr)
*
|
2010-07-26 |
2013-04-05 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application therapeutique
|
MX346635B
(es)
|
2011-02-15 |
2017-03-27 |
Immunogen Inc |
Derivados citotoxicos de la benzodiazepina.
|
WO2012145112A2
(en)
*
|
2011-04-18 |
2012-10-26 |
Immunogen, Inc. |
Novel maytansinoid derivatives with sulfoxide linker
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
AU2012311505B2
(en)
|
2011-09-20 |
2016-09-29 |
Medimmune Limited |
Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
|
KR101891859B1
(ko)
|
2011-10-14 |
2018-08-24 |
메디뮨 리미티드 |
피롤로벤조디아제핀
|
EA036202B1
(ru)
|
2011-10-14 |
2020-10-14 |
Сиэтл Дженетикс, Инк. |
Пирролбензодиазепины и конъюгаты направленного действия
|
EP2750713B1
(en)
*
|
2011-10-14 |
2015-09-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepines and conjugates thereof
|
JP6117801B2
(ja)
|
2011-10-14 |
2017-04-19 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン
|
US9526798B2
(en)
|
2011-10-14 |
2016-12-27 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
DK2817338T3
(en)
|
2012-02-24 |
2017-10-23 |
Abbvie Stemcentrx Llc |
DLL3 modulators and methods of use
|
JP6401060B2
(ja)
|
2012-02-24 |
2018-10-03 |
アッヴィ・ステムセントルクス・エル・エル・シー |
抗sez6抗体及び使用方法
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
RU2014148162A
(ru)
|
2012-05-01 |
2016-06-20 |
Дженентек, Инк. |
Анти-pmel17 антитела и их иммуноконъюгаты
|
KR102433686B1
(ko)
|
2012-05-15 |
2022-08-19 |
씨젠 인크. |
자가-안정화 링커 접합체
|
WO2013177481A1
(en)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazepines and conjugates thereof
|
TW201408698A
(zh)
|
2012-07-09 |
2014-03-01 |
Genentech Inc |
抗cd79b抗體及免疫結合物
|
SG11201500087VA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti-cd22 antibodies
|
WO2014022679A2
(en)
|
2012-08-02 |
2014-02-06 |
Genentech, Inc. |
Anti-etbr antibodies and immunoconjugates
|
EP2887965A1
(en)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Cytotoxic benzodiazepine derivatives
|
AU2013328625B2
(en)
|
2012-10-12 |
2016-12-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
WO2014057120A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
HUE045435T2
(hu)
|
2012-10-12 |
2019-12-30 |
Medimmune Ltd |
Pirrolobenzodiazepinek és konjugátumaik
|
EP2906248B1
(en)
|
2012-10-12 |
2018-12-05 |
MedImmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
HUE042731T2
(hu)
|
2012-10-12 |
2019-07-29 |
Adc Therapeutics Sa |
Pirrolobenzodiazepin-antitest konjugátumok
|
ES2680153T3
(es)
|
2012-10-12 |
2018-09-04 |
Adc Therapeutics Sa |
Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
|
AU2013328673B2
(en)
|
2012-10-12 |
2017-07-13 |
Medimmune Limited |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
SI2906253T1
(sl)
|
2012-10-12 |
2018-11-30 |
Adc Therapeutics Sa |
Konjugati pirolobenzodiazepin-protitelo proti PSMA
|
BR112015008238A2
(pt)
|
2012-10-12 |
2017-11-28 |
Adc Therapeutics Sarl |
conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
EA032986B1
(ru)
|
2012-12-21 |
2019-08-30 |
Медимьюн Лимитед |
Пирролобензодиазепины
|
JP6307519B2
(ja)
|
2012-12-21 |
2018-04-04 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピンおよびその結合体
|
EP2745876A1
(en)
|
2012-12-21 |
2014-06-25 |
Prous Institute for Biomedical Research, S.A. |
Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives
|
MX2015010682A
(es)
|
2013-02-22 |
2016-05-31 |
Stemcentrx Inc |
Nuevos conjugados de anticuerpos y usos de los mismos.
|
EA027910B1
(ru)
|
2013-03-13 |
2017-09-29 |
Медимьюн Лимитед |
Пирролобензодиазепины и их конъюгаты
|
CA2905181C
(en)
|
2013-03-13 |
2020-06-02 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
|
JP6340019B2
(ja)
|
2013-03-13 |
2018-06-06 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
WO2014159835A1
(en)
|
2013-03-14 |
2014-10-02 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
MX2016001862A
(es)
|
2013-08-12 |
2016-08-03 |
Genentech Inc |
Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento.
|
EP3338793A1
(en)
|
2013-08-28 |
2018-06-27 |
AbbVie Stemcentrx LLC |
Novel sez6 modulators and methods of use
|
EP3892294A1
(en)
|
2013-08-28 |
2021-10-13 |
AbbVie Stemcentrx LLC |
Site-specific antibody conjugation methods and compositions
|
JP6332773B2
(ja)
*
|
2013-09-02 |
2018-05-30 |
ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. |
薬物と細胞結合分子との共役のための新規細胞毒性分子
|
CN105518027A
(zh)
|
2013-09-17 |
2016-04-20 |
豪夫迈·罗氏有限公司 |
使用抗lgr5抗体的方法
|
WO2015052534A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
US9956299B2
(en)
|
2013-10-11 |
2018-05-01 |
Medimmune Limited |
Pyrrolobenzodiazepine—antibody conjugates
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
EP3054983B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
US11103593B2
(en)
|
2013-10-15 |
2021-08-31 |
Seagen Inc. |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
RU2016122041A
(ru)
|
2013-11-06 |
2017-12-11 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые анти-клаудин антитела и способы их применения
|
CA2932476A1
(en)
|
2013-12-12 |
2015-06-18 |
Stemcentrx, Inc. |
Novel anti-dpep3 antibodies and methods of use
|
MA39095A1
(fr)
|
2013-12-13 |
2018-08-31 |
Genentech Inc |
Anticorps et immunoconjugués anti-cd33
|
JP6980384B2
(ja)
|
2013-12-16 |
2021-12-15 |
ジェネンテック, インコーポレイテッド |
1−(クロロメチル)−2,3−ジヒドロ−1h−ベンゾ[e]インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
|
JP6713931B2
(ja)
|
2014-02-11 |
2020-06-24 |
シアトル ジェネティクス,インコーポレイティド |
タンパク質の選択的還元
|
JP2017514143A
(ja)
|
2014-02-21 |
2017-06-01 |
アッヴィ・ステムセントルクス・エル・エル・シー |
メラノーマに使用するための抗dll3抗体および薬物コンジュゲート
|
US10464955B2
(en)
|
2014-02-28 |
2019-11-05 |
Hangzhou Dac Biotech Co., Ltd. |
Charged linkers and their uses for conjugation
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
GB201407816D0
(en)
|
2014-05-02 |
2014-06-18 |
King S College London |
Pyrrolobenzodiazepine Compounds
|
MX2016015162A
(es)
|
2014-05-22 |
2017-03-03 |
Genentech Inc |
Anticuerpos anti - gpc3 e inmunoconjugados.
|
WO2016008112A1
(en)
|
2014-07-16 |
2016-01-21 |
Medshine Discovery Inc. |
Linkers and application towards adc thereof
|
AU2015308818B2
(en)
|
2014-08-28 |
2021-02-25 |
Bioatla Llc |
Conditionally active chimeric antigen receptors for modified T-cells
|
KR102626976B1
(ko)
*
|
2014-09-02 |
2024-01-18 |
이뮤노젠 아이엔씨 |
항체 약물 컨쥬게이트 조성물의 제형화 방법
|
JP2017527562A
(ja)
|
2014-09-03 |
2017-09-21 |
イミュノジェン・インコーポレーテッド |
細胞毒性ベンゾジアゼピン誘導体
|
ES2815353T3
(es)
|
2014-09-03 |
2021-03-29 |
Immunogen Inc |
Derivados de benzodiazepina citotóxicos
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗mfi2抗體及使用方法
|
US10188746B2
(en)
|
2014-09-10 |
2019-01-29 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
CA2957354A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
EA201790545A1
(ru)
|
2014-09-12 |
2017-07-31 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты против her2
|
US9751946B2
(en)
|
2014-09-12 |
2017-09-05 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
EP3191518B1
(en)
|
2014-09-12 |
2020-01-15 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
MX2017003523A
(es)
|
2014-09-17 |
2017-11-08 |
Genentech Inc |
Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas.
|
JP6730261B2
(ja)
*
|
2014-09-17 |
2020-07-29 |
ジェネンテック, インコーポレイテッド |
抗her2抗体を含む免疫複合体
|
CN107148285B
(zh)
|
2014-11-25 |
2022-01-04 |
Adc治疗股份有限公司 |
吡咯并苯并二氮杂䓬-抗体缀合物
|
WO2016115201A1
(en)
|
2015-01-14 |
2016-07-21 |
Bristol-Myers Squibb Company |
Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
|
BR112017014599A2
(pt)
|
2015-01-14 |
2018-01-16 |
Bristol-Myers Squibb Company |
dímeros de benzodiazepina, conjugados dos mesmos, e métodos de preparação e uso
|
US9504694B2
(en)
|
2015-03-19 |
2016-11-29 |
Cellerant Therapeutics, Inc. |
Isoquinolidinobenzodiazepines
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
KR20180019592A
(ko)
|
2015-06-23 |
2018-02-26 |
브리스톨-마이어스 스큅 컴퍼니 |
마크로시클릭 벤조디아제핀 이량체, 그의 접합체, 제조법 및 용도
|
CN113350518A
(zh)
|
2015-07-12 |
2021-09-07 |
杭州多禧生物科技有限公司 |
与细胞结合分子的共轭偶联的桥连接体
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
US9873708B2
(en)
|
2015-07-21 |
2018-01-23 |
Immunogen, Inc. |
Methods of preparing cytotoxic benzodiazepine derivatives
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
AU2017237186A1
(en)
|
2016-03-25 |
2018-11-01 |
Seagen Inc. |
Process for the preparation of PEGylated drug-linkers and intermediates thereof
|
CA3021086C
(en)
|
2016-04-15 |
2023-10-17 |
Bioatla, Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
EP3454864A4
(en)
|
2016-04-21 |
2021-01-13 |
Abbvie Stemcentrx LLC |
NOVEL ANTI-BMPR1B ANTIBODIES AND METHOD OF USING
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
WO2017194568A1
(en)
|
2016-05-11 |
2017-11-16 |
Sanofi |
Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
|
SI3455261T1
(sl)
|
2016-05-13 |
2023-01-31 |
Bioatla, Inc. |
Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh
|
JP7022080B2
(ja)
|
2016-05-27 |
2022-02-17 |
ジェネンテック, インコーポレイテッド |
部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
AU2017305170A1
(en)
|
2016-08-02 |
2019-02-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
MA45945A
(fr)
|
2016-08-09 |
2019-06-19 |
Seattle Genetics Inc |
Conjugués de médicaments avec des lieurs auto-stabilisants, aux propriétés physiochimiques améliorées
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
NZ752394A
(en)
|
2016-11-14 |
2021-07-30 |
Hangzhou Dac Biotech Co Ltd |
Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
|
AU2017361887B2
(en)
|
2016-11-21 |
2019-08-15 |
Cureab Gmbh |
Anti-GP73 antibodies and immunoconjugates
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
US11236171B2
(en)
|
2016-12-21 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
ES2890934T3
(es)
|
2017-02-08 |
2022-01-25 |
Adc Therapeutics Sa |
Conjugados de pirrolobenzodiazepinas y anticuerpos
|
JP6671555B2
(ja)
|
2017-02-08 |
2020-03-25 |
アーデーセー セラピューティクス ソシエテ アノニム |
ピロロベンゾジアゼピン抗体複合体
|
US11730822B2
(en)
|
2017-03-24 |
2023-08-22 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
AU2018255876B2
(en)
|
2017-04-18 |
2020-04-30 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
WO2018195243A1
(en)
|
2017-04-20 |
2018-10-25 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives and conjugates thereof
|
AU2018253948A1
(en)
|
2017-04-20 |
2019-09-19 |
Adc Therapeutics Sa |
Combination therapy with an anti-AXL Antibody-Drug Conjugate
|
US11389480B2
(en)
|
2017-05-19 |
2022-07-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
|
MX2019015042A
(es)
|
2017-06-14 |
2020-08-06 |
Adc Therapeutics Sa |
Regimen de dosificacion.
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
KR102270107B1
(ko)
|
2017-08-18 |
2021-06-30 |
메디뮨 리미티드 |
피롤로벤조디아제핀 컨쥬게이트
|
CN111788208B
(zh)
|
2017-09-20 |
2023-11-24 |
Ph制药有限公司 |
泰兰他汀类似物
|
CN111164208B
(zh)
|
2017-09-29 |
2023-08-04 |
第一三共株式会社 |
抗体-吡咯并苯并二氮杂卓衍生物偶联物
|
US11465965B2
(en)
|
2017-11-02 |
2022-10-11 |
Ube Industries, Ltd. |
Double-headed protease inhibitor
|
ES2920123T3
(es)
|
2017-11-14 |
2022-08-01 |
Medimmune Ltd |
Conjugados de pirrolobenzodiazepina
|
WO2019133652A1
(en)
|
2017-12-28 |
2019-07-04 |
Immunogen, Inc. |
Benzodiazepine derivatives
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
EP3801630A1
(en)
|
2018-05-25 |
2021-04-14 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
EP3820903A1
(en)
|
2018-07-12 |
2021-05-19 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Affinity matured cd22-specific monoclonal antibody and uses thereof
|
US20210308275A1
(en)
|
2018-07-31 |
2021-10-07 |
Astrazeneca Ab |
Linkers and conjugates
|
WO2020033430A1
(en)
|
2018-08-08 |
2020-02-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
US20210316006A1
(en)
|
2018-10-19 |
2021-10-14 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
EP3866856A1
(en)
|
2018-10-19 |
2021-08-25 |
MedImmune Limited |
Pyrrolobenzodiazepine conjugates
|
US20220347309A1
(en)
|
2018-12-19 |
2022-11-03 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine resistance
|
GB201820725D0
(en)
|
2018-12-19 |
2019-01-30 |
Adc Therapeutics Sarl |
Pyrrolobenzodiazepine resistance
|
IL297818A
(en)
|
2018-12-21 |
2023-01-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and uses thereof
|
US20220096641A1
(en)
*
|
2019-01-03 |
2022-03-31 |
Legochem Biosciences, Inc. |
Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
|
WO2020146182A1
(en)
|
2019-01-08 |
2020-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
CA3125033A1
(en)
|
2019-01-22 |
2020-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
EP3918323A4
(en)
|
2019-01-30 |
2022-12-28 |
TrueBinding, Inc. |
ANTI-GAL3 ANTIBODIES AND THEIR USES
|
SG11202108900WA
(en)
|
2019-03-15 |
2021-09-29 |
Medimmune Ltd |
Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
|
EP3946464B1
(en)
|
2019-03-29 |
2022-08-31 |
MedImmune Limited |
Compounds and conjugates thereof
|
CN113661172A
(zh)
|
2019-03-29 |
2021-11-16 |
伊缪诺金公司 |
用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物
|
GB201908128D0
(en)
|
2019-06-07 |
2019-07-24 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
CN110483504B
(zh)
*
|
2019-08-02 |
2022-04-26 |
桂林理工大学 |
以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法
|
EP4045511A1
(en)
*
|
2019-10-16 |
2022-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Visual detection of pbd induced dna crosslinks
|
EP4031250A1
(en)
|
2019-10-22 |
2022-07-27 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
|
US20240123081A1
(en)
|
2019-10-25 |
2024-04-18 |
Medimmune, Llc |
Branched moiety for use in conjugates
|
AU2020402752A1
(en)
|
2019-12-12 |
2022-06-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates specific for CD276 and uses thereof
|
US20230097908A1
(en)
|
2020-01-22 |
2023-03-30 |
Medimmune Limited |
Compounds and conjugates thereof
|
TW202140076A
(zh)
|
2020-01-22 |
2021-11-01 |
英商梅迪繆思有限公司 |
化合物及其軛合物
|
JP2023537798A
(ja)
|
2020-03-19 |
2023-09-06 |
アビディティー バイオサイエンシーズ,インク. |
顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
|
WO2021195469A1
(en)
|
2020-03-27 |
2021-09-30 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
IL297167A
(en)
|
2020-04-10 |
2022-12-01 |
Seagen Inc |
Charging variant connectors
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
AU2022238571A1
(en)
|
2021-03-18 |
2023-09-14 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
TW202300179A
(zh)
|
2021-03-18 |
2023-01-01 |
美商西根公司 |
內化的生物活性化合物偶聯物選擇性釋放藥物
|
GB202105187D0
(en)
|
2021-04-12 |
2021-05-26 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
GB202105186D0
(en)
|
2021-04-12 |
2021-05-26 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
CA3216228A1
(en)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
GB202110726D0
(en)
|
2021-07-26 |
2021-09-08 |
Cambridge Entpr Ltd |
Conjugating reagents and conjugates thereof
|
AU2022345098A1
(en)
|
2021-09-16 |
2024-04-04 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
GB202207691D0
(en)
|
2022-05-25 |
2022-07-06 |
Cambridge Entpr Ltd |
Quinone protected forms and conjugates
|